Peroxysome proliferator activated receptors (PPARs): Their role in carbohydrate and lipid metabolism;Récepteurs activables par les proliférateurs des peroxysomes (PPAR): Leur implication dans le métabolisme des hydrates de carbone et des lipides

Annales de Biologie Clinique

Volumn 61, Issue 3, 2003, Pages 295-303

  Andreeva Gateva P ^a  

^a Hôp Univ Tzaritza Joanna   (Bulgaria)

Author keywords

Atherosclerosis; Carbohydrate; Lipide; Nuclear receptor; Obesity

Indexed keywords

CELL RECEPTOR; TRANSCRIPTION FACTOR;

ADIPOCYTE; ARTERIOSCLEROSIS; CARBOHYDRATE METABOLISM; CELL CYCLE; CHEMISTRY; CLASSIFICATION; COCARCINOGENESIS; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIVER CELL; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSIOLOGY; REVIEW;

ADIPOCYTES; ARTERIOSCLEROSIS; CARBOHYDRATE METABOLISM; CELL CYCLE; COCARCINOGENESIS; DIABETES MELLITUS, TYPE 2; HEPATOCYTES; HOMEOSTASIS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; MACROPHAGES; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0038686861     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-D-12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995 ; 83 : 803-12.
2. Chevalier S, Macdonald N, Chevalier N, Roberts R. Stimulation de la croissance hepatocytaire par les proliferateurs de peroxisomes. Med Sci 1999 ; 15 : 1388-94.
3. Bishop-Bailey D. Peroxisome proliferator activated receptors in the cardiovascular system. Br J Pharmacol 2000 ; 129 : 823-34.
4. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990 ; 347 : 645-50.
5. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPAR): novel therapeutic targets in renal disease. Kidney Int 2001 ; 60 : 14-30.
6. Auwerx J. PPAR-γ, the ultimate thrifty gene. Diabetologia 1999 ; 42 : 1033-49.
7. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPAR: from orphan receptors to drug discovery. J Med Chem 2000 ; 43 : 527-49.
8. Ijpenberg A, Jeannis E, Wahli W, Desvergne B. Polarity and specific sequence requirements of PPAR: RXR heterodimer binding to DNA. J Biol Chem 1997 ; 272 : 20108-17.
9. Gervois P, Chopin-Delannoy S, Fadel A, et al. Fibrates increase human REV-ERBα expression in liver via a novel peroxisome-proliferator -activated receptor response element. Mol Endocrinol 1999 ; 13 : 400-9.
10. Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999 ; 3 : 397-403.
11. Clarke SD, Thuillier P, Baillie RA, Sha S. Peroxisome proliferator-activated transcription factors. Am J Clin Nutr 1999 ; 70 : 566-71.
12. Devchand PR, Keller H, Peters JM, Vazquez M, Gonsales EJ, Wahli W. The PPARα-leukotriene B4 pathway to inflammation control. Nature 1996 ; 384 : 39-43
13. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-D-12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995 ; 83 : 803-12.
14. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator activated receptors α and δ. Proc Natl Acad Sci USA 1997 ; 94 : 4312-7.
15. Mukherjee R, Strasser J, Jow L, Hoener P, Paterniti JR Jr, Heiman RA. RXR agonists activate PPARα-inducible genes, lower triglycerides, and rise HDL levels in vivo. Arterioscler Thromb Vasc Biol 1998 ; 18 : 272-6.
16. Zhu Y, Kan L, Qi C, et al. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J Biol Chem 2000 ; 275 : 13510-6.
17. Hermanson O, Glass CK, Rosenfeld MG. Nuclear receptor coregulators: multiple modes of modifications. Trends Endocrinol Metabol 2002 ; 13 : 55-60.
18. Meatiness LM, Miyata KS, Cechetto JD, Rachubinski RA, Capone JP. A mitochondrial ketogenic enzyme regulates its gene expression by association with nuclear hormone receptor PPARalpha. EMBO J 1998 ; 17 : 4920-7.
19. MacDougald O, Mandrup S. Adipogenesis: forces that tip the scales. Trends Endocrinol Metab 2002 ; 13 : 5-11.
20. Aubœuf D, Rieusset J, Fajas R, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans; no alterations in adipose tissue of obese and NIDDM patients. Diabetes 1997 ; 46 : 1319-27.
21. Vidal-Puig A J, Considine RV, Jimenez-Linan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997 ; 99 : 2416-22.
22. Lefebvre AM, Laville M, Vega N, et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 1998 ; 47 : 98-103.
23. Hollenberg AN, Susulic VS, Madura JP, et al. Functional antagonism between CCAAT/enhancer binding protein-α and peroxisome proliferator-activated receptor-γ on the leptin promoter. J Biol Chem 1997 ; 272 : 5283-90.
24. Hofmann C, Lorenz K, Braithwaite SS, et al. Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance. Endocrinology 1994 ; 134 : 264-70.
25. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999 ; 245 : 621-5.
26. Stewart PM, Tomlinson JW. Cortisol, 11β-hydroxysteroid dehydrogenase type 1 and central obesity. Trends Endocrinol Metab 2002 ; 13 : 94-6.
27. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001 ; 294 : 2166-70.
28. Kelly LJ, Vicario PP, Thompson JM, et al. Peroxisome proliferator activated receptors γ and α mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology 1998 ; 139 : 4920-7.
29. Groop L. Genetics of the metabolic syndrome. Br J Nutr 2000 ; 83 (Suppl. 1): S39-S48.
30. Pedraza N, Solanes G, Carmona MC, et al. Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and troglitasone reverse lactation-induced down-regulation of the uncoupling protein-3 gene. Diabetes 2000 ; 49 : 1224-30.
31. Son C, Hosoda K, Matsuda J, et al. Up-regulaton of uncoupling protein 3 gene expression by fatty acids and agonists for PPAR in L6 myotubes. Endocrinology 2001 ; 142 : 4189-94.
32. Hofmann WE, Liu X, Bearden CM, Harper M-E, Kozak LP. Effects of genetic bachground on thermoregulation and fatty acid-induced uncoupling of mitochondria in UCP1-deficient mice. J Biol Chem 2001 ; 276 : 12460-5.
33. Rosmeissl M, Syrovy I, Baumruk F, Flachs P, Janovska P, Kopecky J. Decreased fatty acid synthesis due to mitochondrial uncoupling in adipose tissue. FASEB J 2000 ; 14 : 1793-800.
34. Stefl B, Janovska A, Hodny Z, et al. Brown fat is essential for cold-induced thermogenesis but not for obesity resistance in aP2-Ucp mice. Ant J Physiol 1998 ; 274 : E527-E533.
35. Matthias A, Jacobsson A, Cannon B, Nedergaard J. The bioenergetics of brown fat mitochondrial from UCP1-ablated mice. Ucp1 is not involved in fatty acid-induced de-energization ("uncoupling"). J Biol Chem 1999 ; 274 : 28150-60.
36. Desvergne B, Ijpenberg A, Devchand PR, Wahli W. The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signaling. J Steroid Biochem Molec Biol 1998 ; 65 : 65-74.
37. Bjorntorp P. Neuroendocrine factors in obesity. J Endocrinol 1997 ; 155 : 193-5.
38. Lemberger T, Staels B, Saladin R, Desvergne B, Auwerx J, Wahli W. Regulation of the peroxisome proliferator-activated receptor α gene by glucocorticoids. J Biol Chem 1994 ; 269 : 24527-30.
39. Juge-Aubry CE, Gorlabajszczak A, Pernin A, et al. Peroxisome proliferator activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor: possible role of a leucine zipper-like heptad repeat. J Biol Chem 1995 ; 270 : 18117-22.
40. Keller H, Givel F, Perroud M, Wahli W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol 1995 ; 9 : 794-804.
41. Ma H, Sprecher HW, Kollatukudy PE. Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in PPARγ-expressing tissue. J Biol Chem 1998 ; 273 : 30131-8.
42. Iwashima Y, Eto M, Horiuchi S, Sano H. Advanced glycation end product-induced peroxisome proliferator-activated receptor gamma gene expression in the cultured mesangial cells. Biochem Biophys Res Commun 1999 ; 204 : 441-8.
43. Sartippour MR, Renier G. Differential regulation of macrophage peroxisome proliferator-activated receptor expression by glucose. Atheroscler Thromb Vasc Biol 2000 ; 20 : 104.
44. Pan DA, Mater MK, Thelen AP, Peters JM, Gonsales FJ, Jump DB. Evidence against the peroxisome proliferator-activated receptor α (PPARα) as the mediator for polyunsaturated fatty acid suppression of hepatic L-pymvate kinase gene transcription. J Lip Res 2000 ; 41 : 742-51.
45. Dubois M, Pattou F, Kerr-Conte J, et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000 ; 43 : 1165-9
46. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001 ; 409 : 292-3.
47. Davignon J. Fibrates: a review of important issues and recent findings. Can J Cardiol 1994 ; 10 : 61B.
48. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res 1996 ; 37 : 907-25.
49. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchard J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998 ; 98 : 2088-93.
50. Fruchart J-C, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999 ; 10 : 245-57.
51. Unger RH, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 2001 ; 15 : 312-21.
52. Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM. PPAR-γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998 ; 93 : 241-52.
53. Unger RH, Zhou Y-T, Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci USA 1999 ; 96 : 2327-32.
54. Wang Z-W, Pan W-T, Lee Y, Kakuma T, Zhou Y-T, Unger RH. The role of leptin resistance in the lipid abnormalities of aging. FASEB J 2001 ; 15 : 108-14.
55. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998 ; 391 : 82-6.
56. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997 ; 272 : 3406-610.
57. Subbaramaiah K, Lin DT, Hart JC, Dannenberg AJ. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 2001 ; 276 : 12440-8.
58. Delerive P, J-C Fruchart, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001 ; 169 : 453-9
59. Oliver WR Jr, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001 ; 98 : 5306-11.
60. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001 ; 7 : 53-8.
61. Chinetti G, Gbaguidi FG, Griglio S, et al. CLA-1/SR-B1 is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000 ; 101 : 2411-7.
62. Calvo D, Gomez-Coronado D, Lasuncion MA, Vega MA. CLA-I is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL and VLDL) and modifed (ox-LDL and acLDL) lipoproteins. Arterioscler Thromb Vasc Biol 1997 ; 17 : 2341-9.
63. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998 ; 373 : 25573-80.
64. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998 ; 83 : 1097-103.
65. Hsueh WA, Law RE. Insulin signaling in the arterial wall. Am J Cardiol 1999 ; 84 : 21J-24J.
66. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999 ; 99 : 3125-31.
67. Satoh H, Tsukamoto K, Hashimoto Y, et al. Thiazolidinediones suppress endothelin-1 secretion from bovine endothelial cells: a new possible role for PPARγ on vascular endothelial function. Biochem Biophys Res Commun 1999 ; 254 : 757-63.
68. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor-1 expression. Arterioscler Thromb Vasc Biol 1999 ; 19 : 546-51.
69. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 2001 ; 104 : 1670-5.